Lantern Pharma reports Q2 EPS (46c), one estimate (55c)

Cash, cash equivalents, and marketable securities were approximately $33.3 million as of June 30, 2024, compared to approximately $41.3 million as of December 31, 2023. “The team at Lantern Pharma is making solid, thoughtful and disciplined progress in our clinical trials and in our collaborative research and AI efforts. This past quarter saw a significant milestone where our clinical trials are getting to the point of having initial patient data that we can share, including our unique Harmonic clinical trial for never smokers with lung cancer. We continue to also improve the functionality and abilities of our AI platform, RADR, to guide the next phase of our therapeutic programs which will be heavily marked by trials with combination regimens, and ADC development,” said Panna Sharma, President and CEO of Lantern Pharma.